OncologyPRO: The home of ESMO’s educational and scientific resources

From EAU 2022:
A chart review has found no positive impact of BCG on disease progression in patients with non-muscle-invasive bladder cancer considered high risk as per the new European Association of Urology risk groups

From EAU 2022:
Incorporating multiparametric magnetic resonance imaging into active surveillance for early-stage prostate cancer can reduce the number of biopsies required in the first 3 years

From World GI 2022:
Tucatinib plus trastuzumab regimen has achieved “clinically meaningful” activity in previously treated patients with HER2-positive metastatic colorectal cancer

From World GI 2022:
Frailty, as assessed by a novel scoring system, is associated with worse short-term outcomes after oesophagectomy for oesophageal cancer in patients aged 65 years and older

From World GI 2022:
TOPAZ-1 exploratory analysis suggests that adding durvalumab to gemcitabine plus cisplatin improves advanced biliary tract cancer outcomes irrespective of the primary tumour site

From World GI 2022:
The presence of a BRCAness mutation in advanced biliary tract cancer may be a positive prognostic marker for response to platinum-based chemotherapy

From World GI 2022:
A novel second-generation CTLA4-inhibitor plus PD-1 inhibitor combination has achieved objective responses in patients with microsatellite stable, metastatic colorectal cancer

From ASCO 2022 Annual Meeting:
Preliminary findings indicate that patients with tumours harbouring NRG1 fusions may benefit from treatment with zenocutuzumab or seribantumab